Celecoxib inhibits osteoblast maturation by suppressing the expression of Wnt target genes
Akihiro Nagano1, Masaki Arioka2, Fumi Takahashi-Yanaga3
1Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan; Periodontology Section, Division of Oral Rehabilitation, Faculty of Dental Sciences, Kyushu University, Fukuoka, Japan.
Abstract:
Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to impair bone healing. We previously reported that in colon cancer cells, celecoxib, a COX-2-selective NSAID, inhibited the canonical Wnt/β-catenin signaling pathway. Since this pathway also plays an important role in osteoblast growth and differentiation, we examined the effect of celecoxib on maturation of osteoblast-like cell line MC3T3-E1. Celecoxib induced degradation of transcription factor 7-like 2, a key transcription factor of the canonical Wnt pathway. Subsequently, we analyzed the effect of celecoxib on two osteoblast differentiation markers; runt-related transcription factor 2 (RUNX2) and alkaline phosphatase (ALP), both of which are the products of the canonical Wnt pathway target genes. Celecoxib inhibited the expression of both RUNX2 and ALP by suppressing their promoter activity. Consistent with these observations, celecoxib also strongly inhibited osteoblast-mediated mineralization. These results suggest that celecoxib inhibits osteoblast maturation by suppressing Wnt target genes, and this could be the mechanism that NSAIDs inhibit bone formation and fracture healing.
Insights
Celecoxib, a non-steroidal anti-inflammatory drug (NSAID), inhibits osteoblast maturation by suppressing Wnt pathway target genes, potentially explaining how NSAIDs impair bone healing and fracture repair.
Area of Science:
- Biochemistry
- Cell Biology
- Orthopedics
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) are known to impede bone healing.
- Celecoxib, a COX-2 selective NSAID, was previously shown to inhibit the Wnt/β-catenin pathway in colon cancer cells.
- The Wnt/β-catenin pathway is crucial for osteoblast development and differentiation.
Purpose of the Study:
- To investigate the impact of celecoxib on the maturation of osteoblast-like MC3T3-E1 cells.
- To determine if celecoxib affects key Wnt pathway components and osteoblast differentiation markers.
Main Methods:
- Treatment of MC3T3-E1 cells with celecoxib.
- Analysis of transcription factor 7-like 2 (TCF7L2) degradation.
- Assessment of runt-related transcription factor 2 (RUNX2) and alkaline phosphatase (ALP) expression and promoter activity.
- Evaluation of osteoblast-mediated mineralization.
Main Results:
- Celecoxib induced degradation of TCF7L2, a critical Wnt pathway transcription factor.
- Celecoxib suppressed the expression of RUNX2 and ALP, key osteoblast differentiation markers, by inhibiting their promoter activity.
- Significant inhibition of osteoblast-mediated mineralization was observed in celecoxib-treated cells.
Conclusions:
- Celecoxib inhibits osteoblast maturation through the suppression of Wnt pathway target genes.
- This mechanism may underlie the detrimental effects of NSAIDs on bone formation and fracture healing.
Related Concept Videos
Canonical Wnt Signaling Pathway
Osteoclasts in Bone Remodeling
Inhibition of Cdk Activity
TGF - β Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Bone Formation by Endochondral Ossification

